GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results